{"database": "lobbying", "table": "lobbying_activities", "rows": [[1733039, "ce123943-bfb5-48ae-8ac4-c58ab1d13560", "Q3", "ALKERMES, INC.", 400458235, "ALKERMES, INC.", 2015, "third_quarter", "PHA", "Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances.  \nHR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)", null, 702000, 0, 0, "2015-10-16T09:17:33.987000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1733039"], "units": {}, "query_ms": 45.08671798976138, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}